13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Tumor microenvironment in gastric cancers

      review-article
      1 , , 1 , 1
      Cancer Science
      John Wiley and Sons Inc.
      CAFs, endothelial cells, gastric cancer, gastrin, TAMs

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The tumor microenvironment favors the growth and expansion of cancer cells. Many cell types are involved in the tumor microenvironment such as inflammatory cells, fibroblasts, nerves, and vascular endothelial cells. These stromal cells contribute to tumor growth by releasing various molecules to either directly activate the growth signaling in cancer cells or remodel surrounding areas. This review introduces recent advances in findings on the interactions within the tumor microenvironment such as in cancer‐associated fibroblasts (CAFs), immune cells, and endothelial cells, in particular those established in mouse gastric cancer models. In mice, myofibroblasts in the gastric stroma secrete R‐spondin and support normal gastric stem cells. Most CAFs promote tumor growth in a paracrine manner, but CAF population appears to be heterogeneous in terms of their function and origin, and include both tumor‐promoting and tumor‐restraining populations. Among immune cell populations, tumor‐associated macrophages, including M1 and M2 macrophages, and myeloid‐derived suppressor cells (MDSCs), are reported to directly or indirectly promote gastric tumorigenesis by secreting soluble factors or modulating immune responses. Endothelial cells or blood vessels not only fuel tumors with nutrients, but also interact with cancer stem cells and immune cells by secreting chemokines or cytokines, and act as a cancer niche. Understanding these interactions within the tumor microenvironment would contribute to unraveling new therapeutic targets.

          Abstract

          Gastric tumor microenvironment: Cancer‐associated fibroblasts, endothelial cells, gastrin‐expressing cells, and various immune cells including macrophages, MDSCs, and ILC2s serve as tumor‐promoting niche in gastric cancers. There are numerous crosstalks between tumor cells and surrounding stromal cell types, which contribute to tumor development derived from gastric stem cells.

          Related collections

          Most cited references74

          • Record: found
          • Abstract: found
          • Article: not found

          Origins of tumor-associated macrophages and neutrophils.

          Tumor-associated macrophages (TAMs) and tumor-associated neutrophils (TANs) can control cancer growth and exist in almost all solid neoplasms. The cells are known to descend from immature monocytic and granulocytic cells, respectively, which are produced in the bone marrow. However, the spleen is also a recently identified reservoir of monocytes, which can play a significant role in the inflammatory response that follows acute injury. Here, we evaluated the role of the splenic reservoir in a genetic mouse model of lung adenocarcinoma driven by activation of oncogenic Kras and inactivation of p53. We found that high numbers of TAM and TAN precursors physically relocated from the spleen to the tumor stroma, and that recruitment of tumor-promoting spleen-derived TAMs required signaling of the chemokine receptor CCR2. Also, removal of the spleen, either before or after tumor initiation, reduced TAM and TAN responses significantly and delayed tumor growth. The mechanism by which the spleen was able to maintain its reservoir capacity throughout tumor progression involved, in part, local accumulation in the splenic red pulp of typically rare extramedullary hematopoietic stem and progenitor cells, notably granulocyte and macrophage progenitors, which produced CD11b(+) Ly-6C(hi) monocytic and CD11b(+) Ly-6G(hi) granulocytic cells locally. Splenic granulocyte and macrophage progenitors and their descendants were likewise identified in clinical specimens. The present study sheds light on the origins of TAMs and TANs, and positions the spleen as an important extramedullary site, which can continuously supply growing tumors with these cells.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1.

            We report a paracrine effect whereby endothelial cells (ECs) promote the cancer stem cell (CSC) phenotype of human colorectal cancer (CRC) cells. We showed that, without direct cell-cell contact, ECs secrete factors that promoted the CSC phenotype in CRC cells via Notch activation. In human CRC specimens, CD133 and Notch intracellular domain-positive CRC cells colocalized in perivascular regions. An EC-derived, soluble form of Jagged-1, via ADAM17 proteolytic activity, led to Notch activation in CRC cells in a paracrine manner; these effects were blocked by immunodepletion of Jagged-1 in EC-conditioned medium or blockade of ADAM17 activity. Collectively, ECs play an active role in promoting Notch signaling and the CSC phenotype by secreting soluble Jagged-1. Copyright © 2013 Elsevier Inc. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers

              Tumor-associated macrophages (TAMs) usually express an M2 phenotype, which enables them to perform immunosuppressive and tumor-promoting functions. Reprogramming these TAMs toward an M1 phenotype could thwart their pro-cancer activities and unleash anti-tumor immunity, but efforts to accomplish this are nonspecific and elicit systemic inflammation. Here we describe a targeted nanocarrier that can deliver in vitro-transcribed mRNA encoding M1-polarizing transcription factors to reprogram TAMs without causing systemic toxicity. We demonstrate in models of ovarian cancer, melanoma, and glioblastoma that infusions of nanoparticles formulated with mRNAs encoding interferon regulatory factor 5 in combination with its activating kinase IKKβ reverse the immunosuppressive, tumor-supporting state of TAMs and reprogram them to a phenotype that induces anti-tumor immunity and promotes tumor regression. We further establish that these nanoreagents are safe for repeated dosing. Implemented in the clinic, this immunotherapy could enable physicians to obviate suppressive tumors while avoiding systemic treatments that disrupt immune homeostasis.
                Bookmark

                Author and article information

                Contributors
                yhayakawa-tky@umin.ac.jp
                Journal
                Cancer Sci
                Cancer Sci
                10.1111/(ISSN)1349-7006
                CAS
                Cancer Science
                John Wiley and Sons Inc. (Hoboken )
                1347-9032
                1349-7006
                11 July 2020
                August 2020
                : 111
                : 8 ( doiID: 10.1111/cas.v111.8 )
                : 2696-2707
                Affiliations
                [ 1 ] Department of Gastroenterology Graduate school of Medicine the University of Tokyo Tokyo Japan
                Author notes
                [*] [* ] Correspondence

                Yoku Hayakawa, Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7‐3‐1, Hongo, Bunkyo‐ku, Tokyo, 1138655, Japan.

                Email: yhayakawa-tky@ 123456umin.ac.jp

                Author information
                https://orcid.org/0000-0002-3988-2499
                Article
                CAS14521
                10.1111/cas.14521
                7419059
                32519436
                3b78b93f-a2d6-401b-b653-1d70a6cd0e3d
                © 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                : 22 February 2020
                : 25 May 2020
                : 01 June 2020
                Page count
                Figures: 4, Tables: 1, Pages: 12, Words: 8595
                Funding
                Funded by: Inoue Science Research Award
                Funded by: Advanced Research and Development Programs for Medical Innovation (PRIME)
                Funded by: Kanae Foundation of the Promotion of Medical Science , open-funder-registry 10.13039/501100008880;
                Funded by: KAKENHI Grant‐in‐Aid for Scientific Research
                Award ID: 17K09347
                Award ID: 17H05081
                Funded by: Princess Takamatsu Cancer Research Fund , open-funder-registry 10.13039/501100008886;
                Funded by: Yokoyama Clinical Pharmacological Research Foundation
                Funded by: SENSHIN Medical Research Foundation , open-funder-registry 10.13039/501100008667;
                Funded by: Kowa Life Science Foundation , open-funder-registry 10.13039/501100004088;
                Funded by: Takeda Science Foundation , open-funder-registry 10.13039/100007449;
                Award ID: Visionary Research Grant
                Funded by: Bristol Myers Squibb , open-funder-registry 10.13039/100001009;
                Funded by: Pharmacological Research Foundation
                Funded by: Japan Agency for Medical Research and Development , open-funder-registry 10.13039/100009619;
                Award ID: P‐CREATE
                Categories
                Review Article
                Review Articles
                Custom metadata
                2.0
                August 2020
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.6 mode:remove_FC converted:11.08.2020

                Oncology & Radiotherapy
                cafs,endothelial cells,gastric cancer,gastrin,tams
                Oncology & Radiotherapy
                cafs, endothelial cells, gastric cancer, gastrin, tams

                Comments

                Comment on this article